The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|June 27, 2022
Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer
Author(s)Urology Times staff
“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.
Advertisement
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
4
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
5